AUCTORES
Research Article | DOI: https://doi.org/10.31579/2767-7370/043
1 Professor of Pharmacology, Via Sant’Andrea 32, 56127 Pisa, Italy.
*Corresponding Author: Gian Maria Pacifici, Professor of Pharmacology, Via Sant’Andrea 32, 56127 Pisa, Italy.
Citation: Gian Maria Pacifici, (2023). Biocompatibility of MSC-Seeded Pelvic Patch. J New Medical Innovations and Research, 4(3); DOI:10.31579/2767-7370/043
Copyright: © 2023, Gian Maria Pacifici. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 07 June 2023 | Accepted: 26 June 2023 | Published: 05 July 2023
Keywords: adverse-effects; cerebrospinal-fluid; children; dosing; efficacy-safely; infants; meningitis; pharmacokinetics; prophylaxis; treatment; trimethoprim-sulfamethoxazole
Trimethoprim-sulfamethoxazole is the sulphonamide used in paediatric patients. Trimethoprim-sulfamethoxazole is available as a single-entity preparation and its introduction in clinic has been an important advance in treatment of bacterial infections. Trimethoprim inhibits bacterial dihydrofolate reductase an enzyme downstream form the one that sulphonamides inhibit in the same biosynthetic sequence. This formulation consists in a ratio of sulfamethoxazole:trimethoprin 20:1, may be bactericidal, and in-vivo concentration of sulfamethoxazole is 20-times greater than that of trimethoprim. Trimethoprim-sulfamethoxazole is active against most strains of Staphylococcus aureus and Staphylococcus epidermis, even among methicillin-resistant isolates, viridians group of streptococci, Escherichia coli, Proteus mirabilis, Klebsiella and Enterobacter species, Salmonella, Pseudomonas pseudomallei, Serratia species, Brucella abortus, Pasteurella haemolytica, Yersinia pseudotuberculosis, Yersinia enterocolitica, and Nocardia asteroides. Trimethoprim-sulfamethoxazole has been found efficacy and safe in children but may induce adverse-effects. Both trimethoprim and sulfamethoxazole are rapidly absorbed following oral administration and their absorption-rate constant is 1.27 and 0.58 h-1, respectively. Trimethoprim and sulfamethoxazole inhibits CYP2C8 and CYP2C9, respectively. Prophylaxis and treatment with trimethoprim-sulfamethoxazole have been reviewed and this drug combination treated the meningitis caused by Listeria monocytogenes, Elizabethkingia, Nocardia meningitis, Elizabethkingia meningoseptica, and Staphylococcus aureus. Trimethoprim and sulfamethoxazole are poorly transferred across the human placenta and poorly migrate into the breast-milk. The aim of this study is to review trimethoprim-sulfamethoxazole dosing, efficacy and safely, adverse-effects, interaction with drugs, prophylaxis, treatment and treatment of bacterial meningitis and trimethoprim and sulfamethoxazole pharmacokinetics, penetration into the cerebrospinal fluid, transfer across the human placenta, and migration into the breast-milk.
Trimethoprim-sulfamethoxazole, also known as co-trimoxazole, is the sulphonamide used in paediatric patients. The combination of trimethoprim with sulfamethoxazole is available as a single-entity preparation and trimethoprim-sulfamethoxazole is an important advance in the development of clinically effective and synergistic antimicrobial agents. Trimethoprim-sulfamethoxazole is formulated to have 20-fold higher dose of sulfamethoxazole than trimethoprim. Co-trimoxazole may be administered orally or intravenously, the oral dose in infants is 120 mg/kg twice-daily, and is 240, 480, and 960 mg twice-daily in children aged up to 5, 6 to 11 and 12 to 17 years, respectively. Trimethoprim and sulfamethoxazole are potent inhibitors of CYP2C8 and CYP2C9, respectively, and these drugs are rapidly absorbed following oral administration. Trimethoprim-sulfamethoxazole interacts with drugs, the prophylaxis with trimethoprim-sulfamethoxazole prevents infections caused by different bacteria, and trimethoprim-sulfamethoxazole treats different bacterial infections. Trimethoprim and sulfamethoxazole penetrate into the cerebrospinal fluid in significant amounts, trimethoprim-sulfamethoxazole treats the bacterial meningitis, and trimethoprim and sulfamethoxazole are poorly transferred across the human placenta and poorly penetrate into the breast milk [1].
Mechanism of action of trimethoprim-sulfamethoxazole
Trimethoprim-sulfamethoxazole is a useful antimicrobial drug but must be used when other antibiotics such as penicillins and cephalosporins cannot be employed. The antimicrobial activity of the combination of trimethoprim and sulfamethoxazole results from actions on sequential steps of the enzyme pathway for the synthesis of tetrahydrofolic acid. Tetrahydrofolate is essential for one-carbon transfer reactions (e.g., the synthesis of thymidylate from deoxyuridylate). Mammalian cells use preformed folates from the diet and do not synthesize these compounds. Furthermore, trimethoprim is a highly sensitive inhibitor of dihydrofolate reductase of lower organisms. About 100,000-times more drug is required to inhibit human dihydrofolate reductase than the bacterial enzyme. The optimal ratio of the combinations of the two agents equals the ratio of the MICs of the drugs acting independently. Although this ratio varies from different bacteria, the most effective ratio for the greatest number of microorganisms is 20:1, sulfamethoxazole: trimethoprim. This combination is thus formulated to achieve a sulfamethoxazole concentration in-vivo that is 20-times greater than that of trimethoprim; sulfamethoxazole has pharmacokinetic properties such that the concentrations of the two drugs will thus be relatively constant in the body over a long period. Although each agent alone usually exerts bacteriostatic activity, when the organism is sensitive to both agents, bactericidal activity may be achieved [1].
Antimicrobial activity of trimethoprim-sulfamethoxazole
Although most Streptococcus pneumoniae are susceptible, there has been a disturbing increase in resistance (paralleling the rise in penicillin resistance), and its value for empiric therapeutic use in respiratory-tract infections is questionable. Most strains of Staphylococcus aureus and Staphylococcus epidermis remain susceptible, even among methicillin-resistant isolates, although geographic variation exists. Streptococcus pyogenes is usually sensitive when proper testing procedures (media with low thymidine content) are followed. The viridians group of streptococci is typically susceptible, although susceptibility among penicillin-resistant strains is low. Susceptibility in Escherichia coli varies by geographic region, although it has been declining in general. Proteus mirabilis, Klebsiella species, Enterobacter species, Salmonella, Pseudomonas pseudomallei, Serratia and Alcaligenes species are typically susceptible. Also sensitive are Brucella abortus, Pasteurella haemolytica, Yersinia pseudotuberculosis, Yersinia enterocolitica, and Nocardia asteroides [1].
Figure 1: (A) Molecular weight of trimethoprim = 290.32 grams/mole
(B) Molecular weight of sulfamethoxazole = 253.28 grams/mole.
The literature search was performed electronically using PubMed database as search engine and the following key words were used: “co-trimoxazole dosing infants, children”, “trimethoprim-sulfamethoxazole efficacy, safely infants, children”, “trimethoprim-sulfamethoxazole adverse-effects infants, children”, “trimethoprim and sulfamethoxazole pharmacokinetics infants, children”, “trimethoprim and sulfamethoxazole metabolism”, “trimethoprim-sulfamethoxazole drug interactions”, “trimethoprim-sulfamethoxazole prophylaxis infants, children”, “trimethoprim-sulfamethoxazole treatment infants, children”, “trimethoprim-sulfamethoxazole CSF infants, children”, “trimethoprim-sulfamethoxazole meningitis infants, children” “trimethoprim-sulfamethoxazole placental transfer”, and “trimethoprim-sulfamethoxazole breast-milk”. In addition, the book “The Pharmacological Basis of Therapy” [1] has been consulted.
Treatment of infants and children with co-trimoxazole [2]
Oral treatment of susceptible infections with co-trimoxazole in infants
Infants aged 6 weeks to 5 months. Give: 120 mg twice-daily, alternatively 24 mg/kg twice-daily.
Oral treatment of susceptible infections with co-trimoxazole in children
Children aged 6 months to 5 years. Give: 240 mg twice-daily, alternatively 24 mg/kg twice-daily.
Children aged 6 to 11 years. Give: 480 mg twice-daily, alternatively 24 mg/kg twice-daily.
Children aged 12 to 17 years. Give: 960 mg twice-daily.
Treatment of susceptible infections with oral or intravenous co-trimoxazole in children
Children aged 6 weeks to 17 years. Give: 18 mg/kg twice-daily; increase the dose to 27 mg/kg twice-daily (maximum per dose = 1.44 grams). Increase the dose in severe infections.
Oral or intravenous treatment of Pneumocystis Jirovecil (Pneumocystis carinii) (undertaken where facilities for appropriate monitoring are available) in children
Children. Give: 120 mg/kg daily in 2 to 4 divided doses for 14 to 21 days. The oral route is preferable for children. Consult a microbiologist.
Oral prophylaxis of Pneumocystis Jiroveci (Pneumocystis carinii) infections with co-trimoxazole in children
Children. Give: 450 mg/m2 twice-daily (maximum per dose = 960 mg twice-daily) for 3 days of the week (either consecutively or on alternate days).
Efficacy and safely of trimethoprim-sulfamethoxazole in children
Trimethoprim-sulfamethoxazole is an efficacy and safe treatment of Plasmodium falciparum malaria in children and effectively prevents the malaria caused by Plasmodium falciparum in children [3]. Co-trimoxazole was administered orally at a dose of 16.4 mg/kg for 26 to 59 days to 20 children, aged 9 months to 17 years, suffering from osteomyelitis. Only 8 children (40.0%) had mild adverse-effects, and co-trimoxazole effectively and safely treated osteomyelitis [4]. Seventy-six children, aged 6 months to 13 years, with acute urinary-tract infections were treated with trimethoprim-sulfamethoxazole at a dose of 8/40 mg/kg daily. No treatment failures were observed, mild adverse-effects appeared in only 16.1% of children, and this treatment effectively and safely treated urinary-tract infection [5]. Three-hundred-thirty-four children had no-obstructed urinary-tract infection, 167 children (50.0%) had vesico-ureteric reflux and 27 children (8.1%) had renal scarring. These children were treated with trimethoprim-sulfamethoxazole and neither an increase in recurrent infections was observed nor a significant modification of therapy occurred and trimethoprim-sulfamethoxazole effectively and safely treated urinary-tract infection, vesico-ureteric reflux, and renal scarring [6]. Twenty children suffering from pneumonitis caused by Pneumocystis carinii were treated with 20 mg/kg of trimethoprim and 100 mg/kg sulfamethoxazole daily and the treatment effectively and safely treated the pneumonitis [7].
Adverse-effects caused by trimethoprim-sulfamethoxazole in children
Two-hundred-thirty-four children with melioidosis were treated with trimethoprim-sulfamethoxazole for 3 to 6 months. This treatment caused adverse-effects and a change of treatment or a reduction of the dose necessitated in some children. Of these children, 16 (6.8%) died during treatment and 6 children (2.6%) did not complete the therapy because the adverse-effects [8]. Trimethoprim-sulfamethoxazole was administered to 99 children with intestinal infection caused by Enterobacteriaceae. Initially, trimethoprim-sulfamethoxazole usage was strongly associated with appearance of an integron-positive multidrug-resistant Enterobacteriaceae in the intestinal flora. After prolonged exposure to this drug combination the population of Enterobacteriaceae was substituted by a population with non-integron-associated resistance-mechanisms and after trimethoprim-sulfamethoxazole was discontinued the susceptibility-rate returned to baseline level [9]. Following the administration of trimethoprim-sulfamethoxazole to children the treatment caused cutaneous toxicity (from 1.4 to 7.4% of children), haematological toxicity (from 0 to 72.1% of children), and hepatotoxicity (in 5.0% of children) but serious adverse-effects are extremely rare and are reversible by discontinuance of therapy [10]. The development of haematological abnormalities was evaluated in 50 children who were treated with trimethoprim-sulfamethoxazole. Neutropenia occurred in 34.0% of children and thrombocytopenia developed in 12.0% of children. Neutropenia lasted for 9 days and thrombocytopenia was noted for 13 days and these adverse-effects disappeared after the cessation of treatment [11].
Pharmacokinetics of trimethoprim and sulfamethoxazole in infants and children
Autmizguine et al. [12] studied the pharmacokinetics of trimethoprim and sulfamethoxazole in 153 infants and children with median postmenstrual age, postnatal age, and body-weight of 38 weeks, (range, 32 to 39), 7.9 years (range, 0.1 to 20.2), and 30.8 kg (range, 2.4 to 148), respectively. One-hundred-nine subjects (71.2%) were white, 29 (19.0%) were black 3, and 12 (7.8%) were of other origins. The subject ethnicity was Hispanic 26 (17.0%), not Hispanic 123 (80.3%), and 4 (2.6%) of unknown ethnicity. The median dose of trimethoprim and sulfamethoxazole was 2.5 mg/kg per dose (range, 0.5 to 12.1) and 12.7 mg/kg per dose (range, 2.5 to 60.2), respectively. The median daily dose of trimethoprim and sulfamethoxazole was 4.6 mg (range, 2.5 to 60.2) and 23.0 mg (range, 2.5 to 120), respectively. The median dose interval was 12 hours (range, 6 to 48). Seventy-eight subjects (50.9%) received an oral suspension of trimethoprim-sulfamethoxazole of 8/40 mg/ml at the time of the first recorded dose, while the remaining subjects received trimethoprim-sulfamethoxazole tablets of 80/400 mg or 160/800 mg. Dosing was via the oral route in 125 subjects (81.7%), via a gastrostomy tube 17 subjects (11.1%), and by other routes in 11 subjects (7.2%).
Final model | Bootstrap analysis (N = 1,000) | ||||
Parameter | Estimate | %RSE | 2.5th percentile | Median | 97.5th percentile |
Ka (h-1) | 1.27 | 35.8 | 0.6 | 1.27 | 2.4 |
TBC/F70kg (L/h) | 10.0 | 5.5 | 8.8 | 9.9 | 11.0 |
DV/F70kg (L) | 148 | 6.8 | 129 | 148 | 173 |
TM50 (years) | 0.24 | 24.8 | 0.14 | 0.24 | 0.40 |
Hill | 1 (fixed) | --- | --- | --- | --- |
Exponent for SCR effect on TBC/F | |||||
IIV (TBC/F) (%CV) | 33.8 | 36.8 | 10.0 | 31.6 | 44.7 |
IIV (DV/F) (%CV) | 20.6 | 89.2 | 4.7 | 22.3 | 50.1 |
Proportional error (%) | 51.1 | 4.4 | 42.3 | 50.0 | 57.6 |
RSE = relative standard error. Ka = absorption-rate constant. TBC/F70kg = Total body clearance scaled to a 70 kg adult. DV/F70kg = distribution volume scaled to 70 kg adult. TM50 = maturation elimination half-life calculated as a function of postnatal age (in years). SCR = serum creatinine concentration. IIV (TBC/F) = interindividual variability of total body clearance. IIV (DV/F) = interindividual variability of distribution volume. %CV = %coefficient of variation. F = bioavailability.
Table 1: Pharmacokinetic parameters of trimethoprim which are obtained in 153 infants and children, by Autmizguine et al. [12]
This table shows that trimethoprim is rapidly absorbed following oral administration as the absorption-rate constant is 1.27 h-1, trimethoprim is distributed in a volume larger than the water volume, there is a remarkable interindividual variability in the pharmacokinetic parameters and this variability is accounted by the variation in the subject demographic characteristics.
Median and (range) for the following age groups | ||||
0 to < 2 xss=removed> | 2 to < 6 xss=removed> | 6 to < 21 xss=removed> | Total (N = 153) | |
Parameter | ||||
TBC/F (L/h/kg) | 0.20 (0.05 – 0.44) | 0.23 (0.14 – 0.43) | 0.14 (0.04 – 0.31) | 0.16 (0.04 – 0.44) |
TBC (L/h/70 kg) | 9.6 (1.5 – 18.1) | 11.4 (6.2 – 21.4) | 9.3 (2.5 – 18.0) | 9.6 (1.5 – 21.4) |
DV (L/kg) | 2.1 (1.8 – 2.5) | 2.1 (1.8 – 2.4) | 2.1 (1.4 – 2.4) | 2.1 (1.4 – 2.5) |
DV (L/70 kg) | 149 (125 – 175) | 149 (127 – 171) | 147 (96 – 168) | 148 (96.2 175) |
Elimination half-life (h) | 5.9 (3.3 – 33.2) | 6.5 (3.1 – 11.3) | 11.1 (4.3 – 32.6) | 8.7 (3.1 -33.2) |
TBC = total body clearance. DV = distribution volume. F = bioavailability.
Table 2: Trimethoprim individual empirical Bayesian post hoc parameter estimates which are stratified by age in 153 infants and children. Values are the median and range, by Autmizguine et al. [12].
This table shows that the total body clearance and the distribution volume are independent by the subject age, the elimination half-life increases with the infant maturation and child development, there is a remarkable interindividual variability in the pharmacokinetic parameters and this variability is accounted by the variation in subject age.
Final model | Bootstrap analysis (N = 1,000) | ||||
Parameter | Estimate | %RSE | 2.5th percentile | Median | 97.5th percentile |
Ka (h-1) | 0.58 | 43.9 | 0.1 | 0.60 | 1.3 |
TBC/F70kg (L/h) | 1.46 | 5.1 | 1.30 | 1.45 | 1.76 |
DV/F70kg (L) | 24 | 10.0 | 6 | 23 | 29 |
TM50 (years) | 0.12 | 16.4 | 0.05 | 0.13 | 0.17 |
Hill | 2.13 | 59.6 | 0.3 | 2.3 | 11.4 |
Exponent for ALB effect on TBC/F | |||||
IIV (TBC/F (%) | 35.9 | 46.2 | 9.2 | 33.2 | 51.3 |
IIV DV/F) (%) | 40.6 | 41.1 | 18.3 | 39.6 | 114 |
P (TBC/F – DV/F) | 0.1 | 56.7 | -0.1 | 0.1 | 0.3 |
Proportional error (%) | 46.9 | 16.7 | 34.7 | 45.8 | 53.4 |
Additive error (mg/L) | 5.1 | 38.0 | 1.8 | 5.5 | 322 |
Ka = absorption-rate constant. RSE = relative standard error. TBC/F70kg = total body clearance scaled to a 70 kg adult. DV/F70kg = distribution volume scaled to 70 kg adult. TM50 = maturation elimination half-life calculated as a function of postnatal age (in years). Hill = Hill coefficient in the Emax maturation function. ALB = serum albumin concentration. SRC = serum creatinine concentration. IIV (TBC/F) = interindividual variability of total body clearance. IIV(DV/F) = interindividual variability of the distribution volume. P (TBC/F – DV/F) = correlation between random effect parameters for TBC/F and DV/F. F = bioavailability
Table 3: Pharmacokinetic parameters of sulfamethoxazole which have been obtained in 153 infants and children, by Autmizguine et al. [12].
This table shows that the absorption-rate constant, the total body clearance, and the distribution volume of sulfamethoxazole are smaller than those of trimethoprim and there is a remarkable interindividual variability in the pharmacokinetic parameters and this variability is accounted by the variation in subject demographic characteristics.
AUC0-Γ,ss (mg*h/L) data are the median and (2.5th - 97.5th percentile) | |||||||
Oral dosing twice-daily | Oral dosing thrice-daily | Oral dosing 4 times-daily | |||||
Age group | N. subjects | 8 mg/kg/daya | 12 mg/kg/dayb | 15 mg/kg/dayc | 20 mg/kg/dayd | 15 mg/kg/daye | 20 mg/kg/dayf |
0 to < 2> | 500 | 19.2 (9.2 – 59.1) | 28.7 (13.8 – 88.7) | 23.0 (11.5 – 73.9) | 32.1 (15.4 – 99.0) | 17.9 (8.6 – 55.4) | 23.9 (11.5 – 73.8) |
2 to < 6> | 500 | 19.0 (9.8 – 35.9) | 28.5 (14.7 – 53.8) | 23.8 (12.2 – 44.9) | 31.8 (16.4 – 60.1) | 17.8 (9.2 – 33.6) | 23.8 (12.2 – 44.9) |
6 to 21 years | 1,500 | 22.8 (11.4 – 45.7) | 36.2 (18.0 – 76.5) | 30.7 (15.7 – 63.7) | 41.0 (21.0 – 85.4) | 23.1 (11.8 - 479) | 30.7 (15.7 – 63.7) |
18 to 21 years | 500 | 19.5 (10.2 – 39.5 | 39.1 (20.3 – 79.0) | 42.8 (22.2 – 86.4) | 57.3 (27.7 - 116) | 32.1 (16.6 – 64.8) | 42.8 (22.2 – 86.4) |
AUC0-Γ, ss = AUC at steady-state from 0 to Γ (where Γ denotes the dosing interval). aMaximum daily dose 320 mg (1 double-strength tablet every 12 hours) achieved at a body-weight of 40 kg. bMaximum daily dose 640 mg (2 double-strength tablets every 12 hours) achieved at a body-weight of 53 kg. cMaxumum daily dose 1,200 mg (2 double-strength tables + 1 single-strength tablet every 8 hours) achieved at a body-weight of 60 kg. dMaximum daily dose 1,440 mg (3 double-strength tablets every 8 hours) achieved at a body-weight of 85 kg. eMaximum daily dose 1,200 mg (2 double-strength tablets every 6 hours) achieved at a body-weight of 85 kg. fMaximum daily dose 1,600 mg (2 double-strength tablets + 1 single-strength tablets every 6 hours) achieved at a body-weight of 80 kg.
Table 4: Simulated trimethoprim exposure at steady stale. Values are the median and (range), by Autmizguine et al. [12]
This table shows that the estimates of the area under the concentration-time curve of trimethoprim obtained at the age group of 0 to < 2>
Inhibition of cytochromes P-450 (CYP) by trimethoprim or by sulfamethoxazole
It was evaluated the inhibitory effects of trimethoprim and sulfamethoxazole on recombinant CYP2C8 and CYP2C9. With concentrations ranging from 5 to 100 µM, trimethoprim exhibits a selective inhibitory effect on CYP2C8-mediated paclitaxel 6-alpha-hydroxylation in human liver microsomes and recombinant CYP2C8, with apparent IC50 (Ki) values of 54 µM and 75 µM, respectively. With concentrations ranging from 50 to 500 µM, sulfamethoxazole was a selective inhibitor of CYP2C9-mediated tolbutamide hydroxylation in human liver microsomes and recombinant CYP2C9, with apparent IC50 (Ki) values of 544 µM, and 456 µM, respectively. In conclusion, trimethoprim and sulfamethoxazole can be used as selective inhibitors of CYP2C8 and CYP2C9, respectively [13].
Interaction of trimethoprim-sulfamethoxazole with drugs
Trimethoprim-sulfamethoxazole interacts with warfarin and induces bleeding [14] and concurrent use of vitamin K and trimethoprim-sulfamethoxazole causes blending [15]. Methotrexate and trimethoprim-sulfamethoxazole combination causes extremely serious and life-threatening effects and this drug association should be avoided [16]. Trimethoprim is a potent inhibitor of the renal tubular secretion and can increase plasma concentrations of amantadine, dapsone, digoxin, dofetilide, lamivudine, methotrexate, procainamide, and zidovudine. Trimethoprim can also inhibit sodium channels of the renal distal tubules and may cause hyperkalaemia when it is co-administered with angiotensin-converting enzyme inhibitors. In addition, hyponatremia has been associated with the co-administration of thiazide diuretics and trimethoprim therapy [17].
Prophylaxis with trimethoprim-sulfamethoxazole
Six-hundred-seven infants and children, aged 12 months (range, 2 to 71), were treated with trimethoprim-sulfamethoxazole for 2 years and anthropometric data were completed at 24 months of follow-up in 214 subjects who received the therapy and in 214 subjects who received placebo. Analysis of data revealed that the prophylaxis with this antibiotic does not cause increase of body-weight, prevalence of overweight, or obesity [18]. Short-term prophylaxis with trimethoprim-sulfamethoxazole is effective in controlling Pneumocystis jirovecii infection and preventing future outbreaks of Pneumocystis pneumonia among subjects with rheumatoid arthritis [19]. Prophylaxis with prolonged trimethoprim-sulfamethoxazole prevents Plasmodium falciparum malaria in HIV-exposed children aged up to age 4 years [20]. Long-term prophylaxis with low-dose of trimethoprim-sulfamethoxazole was associated with a decreased number of urinary-tract infections in children [21]. Prophylaxis with trimethoprim-sulfamethoxazole prevents urinary-tract infection in infants and children [22]. Prophylaxis with trimethoprim-sulfamethoxazole effectively prevents Plasmodium falciparum malaria infection and disease and does not select parasites resistant to trimethoprim-sulfamethoxazole [23].
Treatment of bacterial infections with trimethoprim-sulfamethoxazole in infants and children
Trimethoprim-sulfamethoxazole effectively treats Flavobacterium meningosepticum sepsis in infants because of its activity against this organism and the good penetration into the brain [24]. Trimethoprim-sulfamethoxazole treats children infected by Pneumocystis carinii and also treats children with pulmonary and disseminated nocardiosis and some forms of Wegener’s granulomatosis [25]. Trimethoprim and sulfamethoxazole were administered by an intravenous infusion at doses of 5 and 25 mg/kg, respectively, 4 times-daily to 11 infants and children, aged 3 weeks to 13 years, suffering from serious infection caused by Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, or by Acinetobacter anitratus and this treatment cured the infections [26]. Trimethoprim-sulfamethoxazole was administered orally for 3 to 4 days to children, aged 10 months to 15 years, suffering from the infection causes by Salmonella gastroenteritis and this treatment cured the infection [27].
Treatment of bacterial meningitis with trimethoprim-sulfamethoxazole and penetration of trimethoprim and sulfamethoxazole into the cerebrospinal fluid (CSF)
An infant aged 7 month had meningitis caused by Listeria monocytogenes which did not respond to ampicillin and to an aminoglycoside whereas the meningitis was cured with trimethoprim-sulfamethoxazole which was administrate for 3 weeks [28]. An extremely premature infant had the meningitis caused by Elizabethkingia meningoseptica and the meningitis was cured with trimethoprim-sulfamethoxazole [29]. A patient with Nocardia meningitis was treated with trimethoprim-sulfamethoxazole and the meningitis was cured [30]. A single intravenous infusion of 5 mg of trimethoprim and 25 mg of sulfamethoxazole was administered to patients. The peak concentration of trimethoprim and sulfamethoxazole occurred 60 and 480 min, respectively, after the infusion. In the post-infusion phase, the concentration of trimethoprim in the CSF and serum was 0.23 and 0.53 µg/ml, respectively, and that of sulfamethoxazole was 0.20 and 0.36 µg/ml, respectively [31]. Two patients had meningitis caused by Staphylococcus aureus and 4 patients had meningitis due to Listeria monocytogenes and meningitis was cured with trimethoprim-sulfamethoxazole in all patients [32]. Trimethoprim was administered orally and intravenously to patients and trimethoprim penetrates into the CSF in significant amounts even when the meninges are not inflamed [33].
Transfer of trimethoprim and sulfamethoxazole across the human placenta
In literature there is only one study on the transfer of trimethoprim and sulfamethoxazole across the human placenta and has been reported by Bawdon et al. [34]. The placental transfer of trimethoprim and sulfamethoxazole was studied using the perfusion of the placenta. The concentration of trimethoprim in the maternal and foetal compartments was 7.2 µg/ml and 1.4 µg/ml, respectively, at 1 hour of perfusion. When the concentration of trimethoprim was 1.0 µg/ml in the maternal compartment the concentration of trimethoprim in the foetal compartment was 0.08 µg/ml. The concentration of sulfamethoxazole in the maternal and foetal compartments ranged from 29.6 to 127.7 µg/ml and from 5.1 to 14.8 µg/ml, respectively. These results indicate that trimethoprim and sulfamethoxazole are poorly transferred across the human placenta.
Migration of trimethoprim and sulfamethoxazole into the breast-milk
Fourteen lactating women received trimethoprim orally at a daily dose of 320 mg and the peak and trough concentrations of trimethoprim in the milk averaged to 2.4 µg/ml and to 1 µg/ml, respectively. Other 6 lactating women received trimethoprim orally at a daily dosage of 480 mg and the peak and trough concentrations of trimethoprim in the milk averaged to 4 and 1.5 µg/ml, respectively. These results indicate that trimethoprim poorly migrates into the breast-milk [35]. Forty lactating women received co-trimoxazole twice-daily orally equivalent to 800 mg of sulfamethoxazole and 320 mg of trimethoprim. After 5 days of therapy, the concentration of trimethoprim and sulfamethoxazole averaged to 2.0 and 4.5 µg/ml, respectively [36]. These results indicate that trimethoprim and sulfamethoxazole poorly migrate into the beast-milk.
Cell growth and proliferation after nanofibrous scaffold implantation
Trimethoprim-sulfamethoxazole is the sulphonamide used in paediatric patients. Trimethoprim-sulfamethoxazole is a useful antimicrobial drug but must be used when other antibiotics such as penicillins and cephalosporins cannot be employed. Trimethoprim inhibits bacterial dihydrofolate reductase an enzyme downstream form the one that sulphonamides inhibit in the same biosynthetic sequence. The combination of trimethoprim with sulfamethoxazole is an important advance in the development of clinically effective and synergistic antimicrobial agents. Trimethoprim-sulfamethoxazole is available in a single-entity preparation and is also known as co-trimoxazole. The antimicrobial activity of the combination of trimethoprim with sulfamethoxazole results from actions on sequential steps of the activity pathway for the synthesis of tetrahydrofolic acid. Tetrahydrofolate is essential for one-carbon transfer reactions (e.g., the synthesis of thymidylate from deoxyuridylate). Mammalian cells use preformed folates from the diet and do not synthesize these compounds. The optimal ratio of the combinations of the two agents equals the ratio of the MICs of the drugs acting independently and this ratio is 20:1 sulfamethoxazole: trimethoprin. Although each agent alone usually exerts bacteriostatic activity when the organism is sensitive to both agents bactericidal activity may be achieved. Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermis, Streptococcus pyogenes, the viridians group of streptococci, Escherichia coli, Proteus mirabilis, Klebsiella species, Enterobacter species, Salmonella, Pseudomonas pseudomallei, Serratia, Alcaligenes species, Brucella abortus, Pasteurella haemolytica, Yersinia pseudotuberculosis, Yersinia enterocolitica, and Nocardia asteroides are susceptible to trimethoprim-sulfamethoxazole [1]. The oral dose of co-trimoxazole is 120 mg twice-daily in infants and 240, 480, and 960 mg twice-daily in children aged up to 5 years, 6 to 11, and 12 to 17 years, respectively [2]. The efficacy and safely of trimethoprim-sulfamethoxazole have been reviewed. Trimethoprim-sulfamethoxazole effectively and safely treats Plasmodium falciparum malaria in children and the prophylaxis with trimethoprim-sulfamethoxazole prevents Plasmodium falciparum malaria in children [3], prolonged treatment with trimethoprim-sulfamethoxazole effectively and safely treats osteomyelitis in children [4], trimethoprim-sulfamethoxazole effectively and safely treats urinary-tract infection in children [5], urinary-tract infection, vesico-ureteric reflux, and renal scarring in children [6], and pneumonitis caused by Pneumocystis carinii in children [7]. These results indicate that trimethoprim-sulfamethoxazole effectively and safely treats infections caused by different organisms in children. The adverse-effects caused by trimethoprim-sulfamethoxazole have been reviewed. Two-hundred-thirty-four children were treated with trimethoprim-sulfamethoxazole for 3 to 6 months for melioidosis, 16 children (6.8%) died during treatment and 6 children (2.6%) did not complete the therapy because the adverse-effects [8]. Trimethoprim-sulfamethoxazole was administered to 99 children. Initially trimethoprim-sulfamethoxazole was strongly associated with the appearance of integron-positive drug-resistant to Enterobacteriaceae in the intestinal flora. After prolonged exposure to trimethoprim-sulfamethoxazole, however, this population of Enterobacteriaceae was substituted by a population with non-integron-associated resistance mechanisms. After trimethoprim-sulfamethoxazole was discontinued, susceptibility rates to all antibiotics returned to baseline levels [9]. Trimethoprim-sulfamethoxazole causes cutaneous toxicity, haematological toxicity, or hepatotoxicity in some children but the serious adverse-effects are rare and are reversible by discontinuation of therapy [10]. Trimethoprim-sulfamethoxazole causes neutropenia or thrombocytopenia in some children but the adverse-effects disappears after the cessation of treatment [11]. These results indicate that trimethoprim-sulfamethoxazole may cause adverse-effects, the adverse-effects may be serious, but in general disappear with the discontinuous of treatment. The pharmacokinetics of trimethoprim and sulfamethoxazole have been studied by Autmizguine et al. [12] in infants and children who received trimethoprim-sulfamethoxazole orally. Both trimethoprim and sulfamethoxazole are rapidly absorbed with an absorption-rate constant of 1.27 and 0.58 h-1, respectively. In infants and children with a body-weight ranging from 2.4 to 148 kg the total body clearance is 10.0 and 1.46 L/h, scaled to 70 kg, for trimethoprim and sulfamethoxazole, respectively, indicating that trimethoprim is more effectively cleared than sulfamethoxazole. The distribution volume of trimethoprim and sulfamethoxazole, scaled to 70 kg, is 148 and 24 L, respectively, indicating that trimethoprim is distributed in a larger volume than sulfamethoxazole. The elimination half-life of trimethoprim ranges from 5.9 to 11.1 hours and increases with infant maturation and child development. The inhibition of cytochrome P-450 (CYP) by trimethoprim and by sulfamethoxazole has been studied and trimethoprim and sulfamethoxazole are potent inhibitors of CYP2C8 and CYP2C9, respectively [13]. The interaction of trimethoprim-sulfamethoxazole with drugs has been reviewed. The interaction of trimethoprim-sulfamethoxazole with warfarin [14] or with vitamin K [15] induces blending, and the interaction of trimethoprim-sulfamethoxazole with methotrexate induces life-threatening effects [16]. Trimethoprim is a potent inhibitor of the renal tubular secretion and increases the plasma concentration of different drugs. Trimethoprim inhibits sodium channels of the renal distal tubules and may cause hyperkalaemia when it is co-administered with angiotensin-converting enzyme inhibitors. In addition, the co-administration of trimethoprim with thiazine diuretics causes hyponatremia [17]. These results indicate that trimethoprim-sulfamethoxazole interacts with drugs and the interaction may cause serious adverse-effects. The prophylaxis with trimethoprim-sulfamethoxazole has been reviewed. Prophylaxis with trimethoprim-sulfamethoxazole performed for 2 years does not increase body-weight or obesity in children [18], short-term prophylaxis with trimethoprim-sulfamethoxazole controls Pneumocystis jirovecii infection and prevents Pneumocystis pneumonia in subjects with rheumatoid arthritis [19], and the prophylaxis with prolonged trimethoprim-sulfamethoxazole prevents Plasmodium falciparum malaria in HIV-exposed children [20]. Long-term prophylaxis with low dose of trimethoprim-sulfamethoxazole prevents urinary-tract infection in children [21], the prophylaxis with trimethoprim-sulfamethoxazole prevents urinary-tract infection in infants and children [22], and prevents Plasmodium falciparum malaria and does not select parasites resistant to trimethoprim-sulfamethoxazole [23]. These results indicate that the prophylaxis with trimethoprim-sulfamethoxazole does not increase body-weight or obesity in children and prevents urinary-tract infection and Plasmodium falciparum malaria in children. The treatment of bacterial infections with trimethoprim-sulfamethoxazole has been reviewed. Trimethoprim-sulfamethoxazole treats the sepsis caused by Flavobacterium meningosepticum in infants [24], the infection caused by Pneumocystis carinii, disseminated nocardiosis, and Wegener’s granulomatosis in children [25], serious infections caused by Haemophilus influenzae, Streptococcus pneumonia, Streptococcus pyogenes, or by Acinetobacter anitratus in infants and children [26], and treats children infected by Salmonella gastroenteritis [27]. These results indicate that trimethoprim-sulfamethoxazole treats the infection caused by different organisms in infants and children. The treatment of bacterial meningitis with trimethoprim-sulfamethoxazole and the penetration of trimethoprim and sulfamethoxazole into the cerebrospinal fluid have been reviewed. Trimethoprim-sulfamethoxazole administered for 3 weeks treats the meningitis caused by Listeria monocytogenes in infants [28], trimethoprim-sulfamethoxazole treats the meningitis caused by Elizabethkingia meningoseptica in an infant [29], and the meningitis caused by Nocardia meningitis in a patient [30]. Following a single intravenous infusion of 5 mg of trimethoprim and 25 mg of sulfamethoxazole the peak concentration of trimethoprim and sulfamethoxazole occur 60 and 480 min, respectively, after the infusion. In the post-infusion phase, the concentration of trimethoprim in the cerebrospinal fluid and in serum is 0.23 and 0.53 µg/ml, respectively, and that of sulfamethoxazole is 0.26 and 0.36 µg/ml, respectively [31]. Trimethoprim-sulfamethoxazole treats the meningitis caused by Staphylococcus aureus or by Listeria monocytogenes in patients [32], and trimethoprim administered intravenously to patients penetrate into the cerebrospinal fluid in significant amounts even when the meninges are not inflamed [33]. These results indicate that trimethoprim-sulfamethoxazole treats the meningitis caused by different bacteria and trimethoprim and sulfamethoxazole penetrate into the cerebrospinal fluid in significant amounts. The transfer of trimethoprim and sulfamethoxazole across the human placenta has been studied using the perfusion of the placenta and both trimethoprim and sulfamethoxazole are poorly transferred across the human placenta [34]. The migration of trimethoprim and sulfamethoxazole into the breast-milk has been assessed in two studies [35, 36] and both trimethoprim and sulfamethoxazole poorly migrate into the breast-milk.
In conclusion, trimethoprim-sulfamethoxazole is the sulphonamide used in paediatric patients. Trimethoprim-sulfamethoxazole, also known as co-trimoxazole, is a useful antimicrobial drug but must be used when other antibiotics such as penicillins and cephalosporins cannot be employed. Co-trimoxazole is administered at an oral dose of 120 mg twice-daily to infants and at an oral dose of 240, 480, and 960 mg twice-daily to children aged up to 5 years, 6 to 11 years, and 12 to 17 years, respectively. Following the oral administration, trimethoprim and sulfamethoxazole are rapidly absorbed with an absorption-rate constant is 1.27 and 0.58 h-1, respectively. Trimethoprim-sulfamethoxazole has been found efficacy and safe in children but may induce adverse-effects. Trimethoprim-sulfamethoxazole interacts with drugs and the prophylaxis with trimethoprim-sulfamethoxazole prevents bacterial infections and the treatment with this drug combination treats infections caused by different bacteria. Trimethoprim-sulfamethoxazole treats the meningitis caused by different bacteria and trimethoprim and sulfamethoxazole penetrate into the cerebral spinal fluid in significant amounts. Trimethoprim and sulfamethoxazole are poorly transferred across the human placenta and poorly migrate into the breast-milk. The aim of this study is to describe the clinical pharmacology of trimethoprim-sulfamethoxazole in paediatric patients.
Conflicts of Interest
The authors declare no conflicts of financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employments, gifts, and honoraria.
This article is a review and drugs have not been administered to men or animals.
Acknowledgments
The author thanks Dr. Patrizia Ciucci and Dr. Francesco Varricchio, of the Medical Library of the University of Pisa, for retrieving the scientific literature.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.